Loading…

Total Plasma Sulfide in Congestive Heart Failure

Abstract Background Hydrogen sulfide (H2 S) has emerged as a third gaseous transmitter in mammals. In animal models of heart failure, treatment with an H2 S donor can protect the heart against adverse remodeling and attenuate cardiac dysfunction. The aim was to determine total plasma sulfide in pati...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiac failure 2012-07, Vol.18 (7), p.541-548
Main Authors: Kovačić, Dragan, MD, PhD, Glavnik, Nina, MD, Marinšek, Matej, MD, Zagožen, Petra, MD, Rovan, Ksenija, MD, Goslar, Tomaž, MD, Marš, Tomaž, MD, PhD, Podbregar, Matej, MD, PhD
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c423t-46d3202e5f65d631ce3a0011a1986f8ac4a33b43e80210d479f47b7a9ebe0bd93
cites cdi_FETCH-LOGICAL-c423t-46d3202e5f65d631ce3a0011a1986f8ac4a33b43e80210d479f47b7a9ebe0bd93
container_end_page 548
container_issue 7
container_start_page 541
container_title Journal of cardiac failure
container_volume 18
creator Kovačić, Dragan, MD, PhD
Glavnik, Nina, MD
Marinšek, Matej, MD
Zagožen, Petra, MD
Rovan, Ksenija, MD
Goslar, Tomaž, MD
Marš, Tomaž, MD, PhD
Podbregar, Matej, MD, PhD
description Abstract Background Hydrogen sulfide (H2 S) has emerged as a third gaseous transmitter in mammals. In animal models of heart failure, treatment with an H2 S donor can protect the heart against adverse remodeling and attenuate cardiac dysfunction. The aim was to determine total plasma sulfide in patients with congestive heart failure. Methods and Results Total plasma sulfide was determined in 57 patients on admission to an outpatient clinic or cardiology department. Total plasma sulfide concentrations in these patients was lower compared with a control group (5.32 [2.22, 8.00] μM vs. 8.5 [6.00, 14.00] μM; P  = .05). Total plasma sulfide decreased significantly across the New York Heart Association (NYHA) functional classes (II, 5.84 [4.33, 8.00] μM vs. III, 4.67 [4.00, 7.17] μM vs. IV, 2.67 [2.22, 4.31] μM; P  = .001). The total plasma sulfide negatively correlated with pro-BNP (R2 cubic, 0.692; P  = .001) and pulmonary artery systolic pressure (R2 cubic, 0.569; P  = .001). The receiver operating characteristic analysis of the area under the curve for total plasma sulfide as a predictor of mortality was 0.904 (95% CI, 0.822–0.987; P  = .001), and of rehospitalization was 0.779 (95% CI, 0.650–0.908; P  = .001). Total plasma sulfide was a univariate predictor of mortality (odds ratio, 0.245; 95% CI, 0.108–0.555; P  = .001). Conclusion Total plasma sulfide is negatively related to severity of congestive heart failure: it is lowest in NYHA Class IV and in patients with high pro-BNP and high pulmonary artery pressure. Low total plasma sulfide predicts a higher mortality rate.
doi_str_mv 10.1016/j.cardfail.2012.04.011
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1023292182</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1071916412001509</els_id><sourcerecordid>1023292182</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-46d3202e5f65d631ce3a0011a1986f8ac4a33b43e80210d479f47b7a9ebe0bd93</originalsourceid><addsrcrecordid>eNqFkTtPxDAQhC0E4v0XUEqahF3bl0eDQCdeEhJIQG059gb58CVgJyfx7_HpgIKGyi5mdma_ZewEoUDA8mxRGB1sp50vOCAvQBaAuMX2cSZ4XkuU2-kPFeYNlnKPHcS4AIBaQrXL9jivZC3rap_B8zBqnz16HZc6e5p85yxlrs_mQ_9KcXQrym5JhzG7TllToCO202kf6fj7PWQv11fP89v8_uHmbn55nxvJxZjL0goOnGZdObOlQENCQ2qosanLrtZGaiFaKagGjmBl1XSyaivdUEvQ2kYcstPN3PcwfEypiVq6aMh73dMwRYXABW841jxJy43UhCHGQJ16D26pw2cSqTUttVA_tNSalgKpUpdkPPnOmNol2V_bD54kuNgIKG26chRUNI56Q9YFMqOyg_s_4_zPCONd74z2b_RJcTFMoU8cFaqYPOppfbP1yZAnXDNoxBfHIpEd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1023292182</pqid></control><display><type>article</type><title>Total Plasma Sulfide in Congestive Heart Failure</title><source>ScienceDirect Freedom Collection</source><creator>Kovačić, Dragan, MD, PhD ; Glavnik, Nina, MD ; Marinšek, Matej, MD ; Zagožen, Petra, MD ; Rovan, Ksenija, MD ; Goslar, Tomaž, MD ; Marš, Tomaž, MD, PhD ; Podbregar, Matej, MD, PhD</creator><creatorcontrib>Kovačić, Dragan, MD, PhD ; Glavnik, Nina, MD ; Marinšek, Matej, MD ; Zagožen, Petra, MD ; Rovan, Ksenija, MD ; Goslar, Tomaž, MD ; Marš, Tomaž, MD, PhD ; Podbregar, Matej, MD, PhD</creatorcontrib><description>Abstract Background Hydrogen sulfide (H2 S) has emerged as a third gaseous transmitter in mammals. In animal models of heart failure, treatment with an H2 S donor can protect the heart against adverse remodeling and attenuate cardiac dysfunction. The aim was to determine total plasma sulfide in patients with congestive heart failure. Methods and Results Total plasma sulfide was determined in 57 patients on admission to an outpatient clinic or cardiology department. Total plasma sulfide concentrations in these patients was lower compared with a control group (5.32 [2.22, 8.00] μM vs. 8.5 [6.00, 14.00] μM; P  = .05). Total plasma sulfide decreased significantly across the New York Heart Association (NYHA) functional classes (II, 5.84 [4.33, 8.00] μM vs. III, 4.67 [4.00, 7.17] μM vs. IV, 2.67 [2.22, 4.31] μM; P  = .001). The total plasma sulfide negatively correlated with pro-BNP (R2 cubic, 0.692; P  = .001) and pulmonary artery systolic pressure (R2 cubic, 0.569; P  = .001). The receiver operating characteristic analysis of the area under the curve for total plasma sulfide as a predictor of mortality was 0.904 (95% CI, 0.822–0.987; P  = .001), and of rehospitalization was 0.779 (95% CI, 0.650–0.908; P  = .001). Total plasma sulfide was a univariate predictor of mortality (odds ratio, 0.245; 95% CI, 0.108–0.555; P  = .001). Conclusion Total plasma sulfide is negatively related to severity of congestive heart failure: it is lowest in NYHA Class IV and in patients with high pro-BNP and high pulmonary artery pressure. Low total plasma sulfide predicts a higher mortality rate.</description><identifier>ISSN: 1071-9164</identifier><identifier>EISSN: 1532-8414</identifier><identifier>DOI: 10.1016/j.cardfail.2012.04.011</identifier><identifier>PMID: 22748487</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Blood Pressure - physiology ; Cardiovascular ; Case-Control Studies ; Congestive heart failure ; Female ; Heart Failure - blood ; Heart Failure - classification ; Heart Failure - mortality ; Humans ; Male ; Natriuretic Peptide, Brain - blood ; outcome ; Patient Readmission ; Peptide Fragments - blood ; Pulmonary Artery - physiology ; ROC Curve ; Sensitivity and Specificity ; Severity of Illness Index ; sulfide ; Sulfides - blood ; Systole - physiology</subject><ispartof>Journal of cardiac failure, 2012-07, Vol.18 (7), p.541-548</ispartof><rights>Elsevier Inc.</rights><rights>2012 Elsevier Inc.</rights><rights>Copyright © 2012 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-46d3202e5f65d631ce3a0011a1986f8ac4a33b43e80210d479f47b7a9ebe0bd93</citedby><cites>FETCH-LOGICAL-c423t-46d3202e5f65d631ce3a0011a1986f8ac4a33b43e80210d479f47b7a9ebe0bd93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22748487$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kovačić, Dragan, MD, PhD</creatorcontrib><creatorcontrib>Glavnik, Nina, MD</creatorcontrib><creatorcontrib>Marinšek, Matej, MD</creatorcontrib><creatorcontrib>Zagožen, Petra, MD</creatorcontrib><creatorcontrib>Rovan, Ksenija, MD</creatorcontrib><creatorcontrib>Goslar, Tomaž, MD</creatorcontrib><creatorcontrib>Marš, Tomaž, MD, PhD</creatorcontrib><creatorcontrib>Podbregar, Matej, MD, PhD</creatorcontrib><title>Total Plasma Sulfide in Congestive Heart Failure</title><title>Journal of cardiac failure</title><addtitle>J Card Fail</addtitle><description>Abstract Background Hydrogen sulfide (H2 S) has emerged as a third gaseous transmitter in mammals. In animal models of heart failure, treatment with an H2 S donor can protect the heart against adverse remodeling and attenuate cardiac dysfunction. The aim was to determine total plasma sulfide in patients with congestive heart failure. Methods and Results Total plasma sulfide was determined in 57 patients on admission to an outpatient clinic or cardiology department. Total plasma sulfide concentrations in these patients was lower compared with a control group (5.32 [2.22, 8.00] μM vs. 8.5 [6.00, 14.00] μM; P  = .05). Total plasma sulfide decreased significantly across the New York Heart Association (NYHA) functional classes (II, 5.84 [4.33, 8.00] μM vs. III, 4.67 [4.00, 7.17] μM vs. IV, 2.67 [2.22, 4.31] μM; P  = .001). The total plasma sulfide negatively correlated with pro-BNP (R2 cubic, 0.692; P  = .001) and pulmonary artery systolic pressure (R2 cubic, 0.569; P  = .001). The receiver operating characteristic analysis of the area under the curve for total plasma sulfide as a predictor of mortality was 0.904 (95% CI, 0.822–0.987; P  = .001), and of rehospitalization was 0.779 (95% CI, 0.650–0.908; P  = .001). Total plasma sulfide was a univariate predictor of mortality (odds ratio, 0.245; 95% CI, 0.108–0.555; P  = .001). Conclusion Total plasma sulfide is negatively related to severity of congestive heart failure: it is lowest in NYHA Class IV and in patients with high pro-BNP and high pulmonary artery pressure. Low total plasma sulfide predicts a higher mortality rate.</description><subject>Aged</subject><subject>Blood Pressure - physiology</subject><subject>Cardiovascular</subject><subject>Case-Control Studies</subject><subject>Congestive heart failure</subject><subject>Female</subject><subject>Heart Failure - blood</subject><subject>Heart Failure - classification</subject><subject>Heart Failure - mortality</subject><subject>Humans</subject><subject>Male</subject><subject>Natriuretic Peptide, Brain - blood</subject><subject>outcome</subject><subject>Patient Readmission</subject><subject>Peptide Fragments - blood</subject><subject>Pulmonary Artery - physiology</subject><subject>ROC Curve</subject><subject>Sensitivity and Specificity</subject><subject>Severity of Illness Index</subject><subject>sulfide</subject><subject>Sulfides - blood</subject><subject>Systole - physiology</subject><issn>1071-9164</issn><issn>1532-8414</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqFkTtPxDAQhC0E4v0XUEqahF3bl0eDQCdeEhJIQG059gb58CVgJyfx7_HpgIKGyi5mdma_ZewEoUDA8mxRGB1sp50vOCAvQBaAuMX2cSZ4XkuU2-kPFeYNlnKPHcS4AIBaQrXL9jivZC3rap_B8zBqnz16HZc6e5p85yxlrs_mQ_9KcXQrym5JhzG7TllToCO202kf6fj7PWQv11fP89v8_uHmbn55nxvJxZjL0goOnGZdObOlQENCQ2qosanLrtZGaiFaKagGjmBl1XSyaivdUEvQ2kYcstPN3PcwfEypiVq6aMh73dMwRYXABW841jxJy43UhCHGQJ16D26pw2cSqTUttVA_tNSalgKpUpdkPPnOmNol2V_bD54kuNgIKG26chRUNI56Q9YFMqOyg_s_4_zPCONd74z2b_RJcTFMoU8cFaqYPOppfbP1yZAnXDNoxBfHIpEd</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>Kovačić, Dragan, MD, PhD</creator><creator>Glavnik, Nina, MD</creator><creator>Marinšek, Matej, MD</creator><creator>Zagožen, Petra, MD</creator><creator>Rovan, Ksenija, MD</creator><creator>Goslar, Tomaž, MD</creator><creator>Marš, Tomaž, MD, PhD</creator><creator>Podbregar, Matej, MD, PhD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120701</creationdate><title>Total Plasma Sulfide in Congestive Heart Failure</title><author>Kovačić, Dragan, MD, PhD ; Glavnik, Nina, MD ; Marinšek, Matej, MD ; Zagožen, Petra, MD ; Rovan, Ksenija, MD ; Goslar, Tomaž, MD ; Marš, Tomaž, MD, PhD ; Podbregar, Matej, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-46d3202e5f65d631ce3a0011a1986f8ac4a33b43e80210d479f47b7a9ebe0bd93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Blood Pressure - physiology</topic><topic>Cardiovascular</topic><topic>Case-Control Studies</topic><topic>Congestive heart failure</topic><topic>Female</topic><topic>Heart Failure - blood</topic><topic>Heart Failure - classification</topic><topic>Heart Failure - mortality</topic><topic>Humans</topic><topic>Male</topic><topic>Natriuretic Peptide, Brain - blood</topic><topic>outcome</topic><topic>Patient Readmission</topic><topic>Peptide Fragments - blood</topic><topic>Pulmonary Artery - physiology</topic><topic>ROC Curve</topic><topic>Sensitivity and Specificity</topic><topic>Severity of Illness Index</topic><topic>sulfide</topic><topic>Sulfides - blood</topic><topic>Systole - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kovačić, Dragan, MD, PhD</creatorcontrib><creatorcontrib>Glavnik, Nina, MD</creatorcontrib><creatorcontrib>Marinšek, Matej, MD</creatorcontrib><creatorcontrib>Zagožen, Petra, MD</creatorcontrib><creatorcontrib>Rovan, Ksenija, MD</creatorcontrib><creatorcontrib>Goslar, Tomaž, MD</creatorcontrib><creatorcontrib>Marš, Tomaž, MD, PhD</creatorcontrib><creatorcontrib>Podbregar, Matej, MD, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiac failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kovačić, Dragan, MD, PhD</au><au>Glavnik, Nina, MD</au><au>Marinšek, Matej, MD</au><au>Zagožen, Petra, MD</au><au>Rovan, Ksenija, MD</au><au>Goslar, Tomaž, MD</au><au>Marš, Tomaž, MD, PhD</au><au>Podbregar, Matej, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Total Plasma Sulfide in Congestive Heart Failure</atitle><jtitle>Journal of cardiac failure</jtitle><addtitle>J Card Fail</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>18</volume><issue>7</issue><spage>541</spage><epage>548</epage><pages>541-548</pages><issn>1071-9164</issn><eissn>1532-8414</eissn><abstract>Abstract Background Hydrogen sulfide (H2 S) has emerged as a third gaseous transmitter in mammals. In animal models of heart failure, treatment with an H2 S donor can protect the heart against adverse remodeling and attenuate cardiac dysfunction. The aim was to determine total plasma sulfide in patients with congestive heart failure. Methods and Results Total plasma sulfide was determined in 57 patients on admission to an outpatient clinic or cardiology department. Total plasma sulfide concentrations in these patients was lower compared with a control group (5.32 [2.22, 8.00] μM vs. 8.5 [6.00, 14.00] μM; P  = .05). Total plasma sulfide decreased significantly across the New York Heart Association (NYHA) functional classes (II, 5.84 [4.33, 8.00] μM vs. III, 4.67 [4.00, 7.17] μM vs. IV, 2.67 [2.22, 4.31] μM; P  = .001). The total plasma sulfide negatively correlated with pro-BNP (R2 cubic, 0.692; P  = .001) and pulmonary artery systolic pressure (R2 cubic, 0.569; P  = .001). The receiver operating characteristic analysis of the area under the curve for total plasma sulfide as a predictor of mortality was 0.904 (95% CI, 0.822–0.987; P  = .001), and of rehospitalization was 0.779 (95% CI, 0.650–0.908; P  = .001). Total plasma sulfide was a univariate predictor of mortality (odds ratio, 0.245; 95% CI, 0.108–0.555; P  = .001). Conclusion Total plasma sulfide is negatively related to severity of congestive heart failure: it is lowest in NYHA Class IV and in patients with high pro-BNP and high pulmonary artery pressure. Low total plasma sulfide predicts a higher mortality rate.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>22748487</pmid><doi>10.1016/j.cardfail.2012.04.011</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1071-9164
ispartof Journal of cardiac failure, 2012-07, Vol.18 (7), p.541-548
issn 1071-9164
1532-8414
language eng
recordid cdi_proquest_miscellaneous_1023292182
source ScienceDirect Freedom Collection
subjects Aged
Blood Pressure - physiology
Cardiovascular
Case-Control Studies
Congestive heart failure
Female
Heart Failure - blood
Heart Failure - classification
Heart Failure - mortality
Humans
Male
Natriuretic Peptide, Brain - blood
outcome
Patient Readmission
Peptide Fragments - blood
Pulmonary Artery - physiology
ROC Curve
Sensitivity and Specificity
Severity of Illness Index
sulfide
Sulfides - blood
Systole - physiology
title Total Plasma Sulfide in Congestive Heart Failure
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T21%3A13%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Total%20Plasma%20Sulfide%20in%20Congestive%20Heart%20Failure&rft.jtitle=Journal%20of%20cardiac%20failure&rft.au=Kova%C4%8Di%C4%87,%20Dragan,%20MD,%20PhD&rft.date=2012-07-01&rft.volume=18&rft.issue=7&rft.spage=541&rft.epage=548&rft.pages=541-548&rft.issn=1071-9164&rft.eissn=1532-8414&rft_id=info:doi/10.1016/j.cardfail.2012.04.011&rft_dat=%3Cproquest_cross%3E1023292182%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c423t-46d3202e5f65d631ce3a0011a1986f8ac4a33b43e80210d479f47b7a9ebe0bd93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1023292182&rft_id=info:pmid/22748487&rfr_iscdi=true